Atossa reports 170 patients enrolled in Phase 2 Karisma-Endoxifen trial

Atossa Therapeutics announced that 170 patients have been enrolled in the Company’s ongoing Phase 2 Karisma-Endoxifen clinical trial. Atossa expects the study to fully enroll in the fourth quarter of 2023. The Karisma-Endoxifen trial is a randomized, double-blind, placebo-controlled efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density. Participants receive daily doses of (Z)-endoxifen for six months, over the course of which mammograms are conducted to measure reduction in mammographic breast density. Participants will also have a mammogram at 24 months to assess the durability of the MBD changes.